Quick Answer
4D Molecular Therapeutics, Inc. reported Cash and Equivalents of $60.24 million for fiscal year 2025.
4D Molecular Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $60.24M | -59.7% |
| 2024 | $149.34M | -40.1% |
| 2023 | $249.11M | +375.8% |
| 2022 | $52.35M | -65.8% |
| 2021 | $153.00M | -44.7% |
| 2020 | $276.73M | +457.3% |
| 2019 | $49.65M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $48.55M | -74.1% | -37.1% |
| June 30, 2025 | $77.16M | -59.2% | -42.2% |
| March 31, 2025 | $133.53M | -51.5% | -10.6% |
| December 31, 2024 | $149.34M | -40.1% | -20.4% |
| September 30, 2024 | $187.54M | -32.0% | -0.8% |
| June 30, 2024 | $189.06M | -20.0% | -31.4% |
| March 31, 2024 | $275.59M | +250.8% | +10.6% |
| December 31, 2023 | $249.11M | +375.8% | -9.6% |
- 4D Molecular Therapeutics, Inc. showed a decrease of -59.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, 4D Molecular Therapeutics, Inc.’s cash and equivalents has grown by 21.3% (from $49.65 million to $60.24 million).
- The most recent figure is from 4D Molecular Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: